Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
The Business Research Company (TBRC), a market research and intelligence firm, released a promising analysis of the global psoriatic arthritis treatment market.
At the Brigham and Women’s Hospital, a male patient with Secondary Progressive Multiple Sclerosis serves as a beacon of hope for those afflicted with the same neurodegenerative disease.
Denali initiates dosing in Phase I/II frontotemporal dementia study. Intellia snags Orphan Drug Designation for experimental T cell receptor (TCR)-T cell therapy, NTLA-5001 in AML.
Researchers saw that programmed death ligand 1 on dendritic cells could control adaptive immune responses within adipose tissues to limit diet-induced obesity.
Morningside Ventures launched a new biotech company called Adiso Therapeutics, and thriving startup Scenic Biotech scooped up €28 million ($31 million) in funding.
Bancel reaped the rewards of SpikeVax’s success, but the Boston Business Journal noted that annual compensation for Moderna’s median employee plunged 16%.
Financial fraud committed by supposed online pharmacies may be as big a threat to society as counterfeit medicines.
Gilead Sciences is letting go of 114 employees following an underwhelming response to the results reaped so far from its $21 billion acquisition of Immunomedics in 2020.
Two months after he received a gene-edited pig heart, David Bennett Sr. has died. He was 57.
Recent technological advancements have pushed pharma employees to embrace new technologies and innovations in different areas.
This target date is the latest development in a long series of setbacks that Acadia - and other pharma companies - have experienced getting Alzheimer’s treatments approved.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
PRESS RELEASES
• Augurex’s SPINEstat® (Anti-14-3-3eta Multiplex for axial spondyloarthritis) test has been selected as a finalist in the ADLM 2026 Disruptive Technology Award, one of laboratory medicine’s most competitive recognition programs. • Augurex will present at ADLM 2026 on July 27 in Anaheim, CA, with a dedicated finalist kiosk on the Expo Floor July 28–30. • The recognition underscores Augurex’s leadership in developing biomarker-driven diagnostics that address critical unmet needs across autoimmune and inflammatory diseases.
